The Treatment of Hormone Refractory Prostate Cancer
- 1 March 2003
- journal article
- Published by Elsevier in EAU Update Series
- Vol. 1 (1) , 40-50
- https://doi.org/10.1016/s1570-9124(03)00008-4
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer PatientsJournal of Clinical Endocrinology & Metabolism, 2001
- Docetaxel and exisulind in hormone-refractory prostate cancerSeminars in Oncology, 2001
- Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancerSeminars in Oncology, 2001
- THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCERJournal of Urology, 2001
- Treatment Options in Hormone-Refractory Prostate CancerDrugs, 2001
- Current clinical trial design issues in hormone-refractory prostate carcinomaCancer, 1998
- Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II studyZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 1991
- Morphometric Evidence for Bone Resorption and Replacement in Prostate CancerBritish Journal of Urology, 1991
- Mechanisms of Action and Clinical Uses of EstramustineCancer Investigation, 1990